News
Moderna CEO Says COVID-19 Vaccine Could Get Emergency Approval in December
As the top three COVID-19 vaccine projects get closer to the finish line, everybody is paying attention to when they might be available. Moderna...
News
Brazil COVID-19 vaccine trial continues despite volunteer death
Clinical trials of the Covid-19 vaccine being developed by Oxford University and AstraZeneca PLC will continue in Brazil despite the death a volunteer, Brazilian...
Drug Research
BioIVT Launches HEPATOMUNE Kit to Facilitate Liver Toxicity and Inflammation Studies for Drug Discovery and Disease Research
BioIVT, a leading provider of research models and services for drug and diagnostic development, launched its HEPATOMUNEยฎ kit, a long-term, stable, in vitro model...
Drug Research
Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment
Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its...
Press Releases
Valicare GmbH extends GxP expertise
Valicare GmbH, a wholly owned subsidiary of Syntegon, now offers additional services along the entire product life cycle of pharmaceutically and biotechnologically produced drugs....
Clinical Trials
GSK presents positive clinical data on maternal and older adults RSV candidate vaccines
GSK announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunisation (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in...
News
AstraZeneca’s Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD
AstraZenecaโs Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been recommended for marketing authorisation in the European Union (EU) for maintenance treatment in adult patients with...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
















